1. Cancer Research at UNC: Lineberger CCC Update
Why I took this job:
I was offered job running oncologic drug discovery at large pharma. While considering that option, I realized I was passionate about basic cancer research and its clinical translation. Given my love for UNC, I could not imagine better place to be Cancer Center Director
Lisa A. Carey, MD
Jacobs Preyer Distinguished Professor for Breast Cancer Research
Associate Director, Clinical Sciences
Lineberger Comprehensive Cancer Center

2. UNC Lineberger:
NC’S PUBLIC COMPREHENSIVE CANCER CENTER. AREAS OF FOCUS Basic Research Population Sciences Research Clinical and Translational Research Dissemination and outreach in NC Economic Development Clinical Excellence
NC’s Matrix Ca Ctr embedded within UNC

3. UNC Lineberger History
“Comprehensive” Designation
Marsico Hall
University Cancer Research Fund Starts
NC Cancer Hospital
1974
1990
1995
2008
2009
2014
NCI Designation;
Joe Pagano, PhD
First Director
H. Shelton Earp III, MD Second Director
Norman E Sharpless, MD
Third Director

4. LCCC: Who We Are And How We Do It
2010
2014
LCCC Members
295
300
LCCC space (square feet)
100K
153K
NCI Funding
$64m
$71m
All Cancer Funcing
$220m
$210m
Cancer Patients on Trials
Testing Interventions
1,079
1,731
Take home is we are vibrant growing cancer center
Great growth in accruals, NCI funding, PPGS, space
Membership and funding have held steady b/c advice of our EAB, as new director, to enhance cancer focus. Scrutinized grants and membership; and reduced both significantly
Members have $280M in funding.

5. Growth in NCI Funding 2014 NCI FUNDING: Stanford $55M Michigan $54M
Wash U $42M
Duke $34M
UNC $58M
(6th among matrix cancer centers) 25

6. One of the Reasons UNC is Great
NC Cancer Hospital
UNC Lineberger
Marsico Hall
Dental School
School of Nursing
Eshelman School of Pharmacy
Gillings School of Global Public Health

7. RESEARCH PROGRAMS

8. Cancer in North Carolina
Cancer Deaths/100K
Key AA-White Mortality Disparities
Lung (53.2)
Prostate (2.8-fold)
Prostate (23.4)
Endometrial (2.3-fold)
Breast (22.4)
Myeloma (2.2-fold)
Colon (14.8)
Head &Neck (2.0-fold)
Pancreas (10.5)
Cervix (1.9-fold)
Colon (1.5-fold)
Breast (1.4-fold)
Population: 9.9M
Annual Cancer Cases: 52,550
Annual Cancer Deaths: 19,300
22% African American, 9% Hispanic

9. UNC LCCC Disparities Research
Prostate – North Carolina-Louisiana Prostate Cancer Project Endometrial – minority obesity interventions/metformin trial Multiple Myeloma –North Carolina Multiple Myeloma Network Head and Neck – Carolina Head and Neck Cancer Study Cervical – HPV vaccine and screening interventions Colorectal – Colonoscopy interventions in African-American and Hispanic populations Breast – Carolina Breast Cancer Study Lung – Intervention to increase early detection and lung cancer surgery in African American populations Bladder – Investigating sub-types in African American populations

10. Understanding Cancer in NC: ICISS
Combines Tumor Registry: 100% - 320,000 cases ( )
With Health Care Claims: Medicare, Medicaid, private payers, State Employees
= 80% of NC cancers (~255,000 cases)
Involves 4 UNC schools, 16 departments, 4 programs
Powerful tool: Understanding how patients are being treated in NC & how well they do
STEPHANIE WHEELER
(SPH)
ETHAN BASCH
(Heme/Onc)
RON
CHEN
(Radiation Onc)
ANNE-MARIE MEYER
(SPH)

11. Carolina Breast Cancer Study (CBCS)
Large population-based study of breast cancer
Combined classical and molecular epidemiology.
CBCS1 ( ); CBCS2 ( ).
CBCS1/2: >100 Publications
CBCS , followup x 10y
ANDY OLSHAN
(Chair, UNC Epi)
Enrollment by Race
Identified Black/White disparities in:
Type of breast cancer
Access and adherence to drugs
Survival

12. Cancer Genetics: National Leadership
CHUCK PEROU,
KATIE HOADLEY
LCCC 1108 –UNCseq
Over 1,700 patients consented
28 tumor types
10,000 samples
>100 trillion bases
NEIL HAYES
--Hoadley, Cell, 2014

13. LCCC Sequencing Trials
DNA
RNA
CBCS3 (3,000 germlines)
TCGA (10,000 tumors)
Integrated Translational Science Center
Integrated Translational Science Center (tumor)
Retrospective
CBCS3 (3,000 tumors)
Investigator-initiated studies
National Cooperative Group trials
Investigator-initiated studies
UNCseq (1,700 patients to date, tumor and germline)
UNCseq
Integrated Translational Science Center
Integrated Translational Science Center (tumor)
Qiuickly say this is provided as reference
Prospective
“Window” drug trials in melanoma, breast cancer, lymphoma
NCGenes (germline)

14. Novel Tech: Carbon Nanotube X-rays
DEPT. OF PHYSICS AND ASTRONOMY WORKING
WITH CLINICAL RADIOLOGY
SMALLER, COOLER X-RAY SOURCES
CLINICAL APPLICATIONS
Chest, breast, dental radiography
Hi-energy sources for radiation oncology
OTTO ZHOU
Just point out here that
does radiology and rad onc
Comes out of Dept of Physics and Astronomy, now in human clinical trials with CR program (10 minute walk)
RAY LEE

15. Novel Tech: Kinome Profiling
Identifying ways that cancer cells RESIST targeted therapy
GARY JOHNSON
PhD
Trials ongoing in melanoma, lung, pancreas, lymphoma and breast cancer
LISA CAREY MD
STERGIOS MOSCHOS MD

16. Mouse Avatars: Studying Cancer and Drugs
COLLABORATIVE CROSS
MOUSE PHASE I UNIT
50+ partners in academia and industry
40+ publications (e.g. Cell, Nature, Cancer Cell, Cancer Disco.)
32 funded grant proposals: $25M
5,000 cages for serial housing
Small animal imaging (PET/CT, Optical, MRI, U/S)
Pharmacokinetics and Pharmacodynamic Monitoring
Sharpless et al., Cell 2013
Genetically engineered mice
80+ publications since 2011

17. Global Oncology NEW NCI FUNDING: U54, NCI supplement (7), R21 (2)
DIRK DITTMER
BLOSSOM DAMANIA
TATA MEMORIAL, MUMBAI
MALAWI / ZAMBIA PARTNERSHIP
GROESBECK PARHAM
YURI FEDORIW
SAO PAULO CANCER CENTER
MALAWI CANCER PROGRAM
JENNIFER SMITH
SATISH GOPAL

18. Patient-Reported Outcomes
Methodological leadership of major initiatives at NCI, FDA, PCORI, industry (including development of NCI’s PRO-CTCAE)
BRYCE REEVE
ETHAN BASCH
NEW DEVELOPMENTAL PRO SHARED FACILITY (“PRO-CORE”)
Hired software developer
Two psychometricians
INVOLVES MULTIPLE INVESTIGATORS ACROSS CLINICAL AND PREVENTION PROGRAMS AT LCCC
“Patient-reported outcomes is an area of particular strength at UNC, with 6 faculty recruits since the last review including Dr. Bryce Reeve from the NCI, and Dr. Ethan Basch from MSK, who each lead major national and international initiatives in this area.  PROs are now being widely being used by cancer center investigators across multiple programs in clinical research, clinical care, and in registries, and we have a new developmental PRO shared facility to support these efforts.”

19. Tobacco Centers of Regulatory Science Awards
Impact of Tobacco Exposure on Lung’s Innate Defense System
Communication on Tobacco Product Risk and FDA Authority
Kurt M. Ribisl, PhD
Communicating risk to different communities and with different products. Inform FDA regulation.
Robert Tarran, PhD
All forms of tobacco exposure
There are 14 Tobacco Centers of Regulatory Science funded by NIH. (Both are about $19M each if you want to say that)
UNC is the only university with 2 TCORS Centers centers. See
One is led by Kurt Ribisl in CPC and the other by Robert Tarran in Cell Biology.
Both centers focus on cigarettes, e-cigarettes, and little cigars
Dr. Tarran’s focuses on testing the impact on lung tissue of these 3 products.
Dr. Ribisl’s P50 focuses on communicating with tobacco users in new ways about the risks of these products.
Early work suggests that flavored e-cigarettes are particularly toxic. This is important because FDA is considering restricting flavors.
(if time) Tarran and Ribisl are in regular communication about their studies and help each other out. (Tarran, a basic scientist, recently asked Ribisl which ecig brands to test and Ribisl had market share data that he shared)

20. Discovering Cancer Drugs
CENTER FOR INTEGRATIVE CHEMICAL BIOLOGY AND DRUG DISCOVERY (CICBDD)
Cancer drugs in development
Scientific focus for future drugs
Expansion in 2016
STEPHEN FRYE CICBDD DIRECTOR

21. New Immunotherapy Program
>$20M Investment
Manufacturing Facility:
Opening 2016
6 T-cell expansion rooms and viral production
New Faculty:
Barbara Savoldo and Gianpietro Dotti, national leaders, recruited from Baylor.
New facility director from St Jude
FIRST TRIAL TO START AT UNC IN 2016!

22. Entrepreneurship

23. SUMMARY Cancer research at UNC is huge and successful
Centered at LCCC, one of the nation’s oldest and largest cancer centers
Excellence in public health research, clinical translation, genetics, drug discovery, “big data” analytics and mouse models.
Emerging programs in immunotherapy and novel imaging.

24. Questions?